A post-hoc pooled analysis of two placebo controlled phase 3 trials, Assessment of Weekly AdministRation of LY2189265 in Diabetes -1 and -5 (AWARD-1 and AWARD-5): dulaglutide comp…

Aim: To compare once weekly dulaglutide 1.5 mg and dulaglutide 0.75 mg with placebo at 26 weeks, and with sitagliptin 100 mg once daily (AWARD-5) and exenatide 10 µg twice daily (AWARD-1) at 26 and 52 weeks in patients with Type 2 diabetes with a mean baseline HbA1c of approximately 8%. Methods: Data from the dulaglutide 1.5 mg, dulaglutide 0.75 mg or placebo arms were pooled by treatment. Comparisons were made for change (LS mean [SE]) in HbA1c and percentage of patients achieving HbA1c targets of < 7% and ≤6.5% at 26 weeks and 52 weeks. Results: At 26 weeks, dulaglutide 1.5 mg and dulaglutide 0.75 mg showed re…